Federal Resources sat down with MRO industry and market expert Tim Langan from SERE Industries to weigh-in on the current field first-aid situation and what solutions are out there to modernize these capabilities.
A: The first concern is stopping life threatening hemorrhage, which is the number one preventable killer on the battlefield. Hemorrhagic shock is still the main cause of battlefield mortality and the second most prevalent cause of mortality in civilian trauma. Secondly, advanced SOP’s with respect to certifications for bi-annual training to all personnel on Individual First-Aid Kits (IFAK) would be beneficial as well to our military.
A: “The use of hemostatic dressings and agents is one of the main advancements achieved in recent decades. However, it can be claimed that the ideal hemostatic has not been recognized yet; therefore, this topic needs to be brought into focus and further addressed” [1]
Currently, some of the treatment options for external battlefield wounds include Chitosan, Kaolin, and Zeolite. Chitosan, derived from shrimp shells, can cause carbamate toxins and anaphylaxis as shrimp is cross-reacting allergen. Kaolin, a Chinese clay, runs the risk of skin irritation and respiratory exposure that can tear from the cell wall. Zeolite, a volcanic rock, is associated with exothermic reactions, as well as or vascular complications. “There were mild edematous and vacuolar changes in nerve samples” that were treated with Zeolite.
There are other combination-product wound dressings for external wounds that are effective in the short run, but not so much in the long run. One of these combination-products is thrombin, which can be useful for controlling minor bleeding from capillaries and small venules, but ineffective and not indicated for massive or brisk arterial bleeding.
Wound dressings for external wounds that include zeolite, various clays (bentonite or kaolin are principal examples), bandage, and sponge products with other combined products mentioned above can cause further hemorrhaging upon removal.
It’s important to note: All of these current products make life more difficult for the medical professionals who have to deal with the injured patient. Subsequently these products traumatize the fragile and damaged tissue further and have to be removed or irrigated within 24 hours.
A: The “Samaritan” compound can be applied to all first-aid or wound management needs. The product can be color coded for specific injury markers, and /or completely opaque or transparent for numerous applications or classifications in wound treatment. The Samaritan product can deliver a "bioactive" layer, of specific impregnated Nano particles or special elements to distribute antibiotics, pain medication, treat for shock and to prevent systemic fungal and/or bacterial infections with broad-spectrum activity. Samaritan does not need to be irrigated every 24 hours or removed. It can be left on the wound for up to 29 days.
A: The “Samaritan” product is a lifesaving revolutionary game changer. Essentially Samaritan is a fusible flexible proprietary compound used primarily for combat casualty care to STOP BLEEDING, dress wounds, or prep the area for further medical treatment to begin promoting effective cellular healing. Samaritan is a fully biodegradable, non-breathable product that and adheres to the skin, with no separate taping needed. Samaritan has a superior super effect, that acts as “molecular glue” which reinforces the hemostatic process providing rapid and accelerated coagulation or blood clotting that quickly stops and reduces the amount of bleeding present. Samaritan can be easily applied on open wounds such as any skin injury caused by abrasion with road surfaces, explosions, or common battlefield scrapes. When applied Samaritan flows into microscopic grooves. It does not tear away from the wound or cell wall and can be easily removed in one piece. The blood vessels remain occluded after removal. Samaritan can be seen inside the wound as Barium can be added for x-raying purposes.
The benefits of Samaritan treatment are multi-dimensional and will overlap across a broad spectrum of environments or marketing sectors. The Samaritan product and individual delivery systems will solve dynamic medical and health-related problems that compromise the safety, or deter the mission performance of Soldier, Sailor, and Aviator. The product will provide multiple applications for use in proper crisis management in diverse areas of operation, especially as a means to provide rapid triage for mass casualty care for first responders and civilians around the world.
BASIC product ingredients are all FDA cleared. The general product is meeting all 5 requirements for future full FDA approval:
SHELF LIFE OF THE BASIC SAMARITAN
EXTREME TEMPERATURES
For more information on the Samaritan treatment, please contact scott.graham@julianneg3.sg-host.com.
A: The goal should be to provide the first choice for high quality and innovative medical products, logistics support and training along with advanced SME liaison to support U.S. and allied forces deployed to U.S. European and U.S. Central Commands. If our customers can work with industry to enhance product application for mitigation of medical threats and collaboration wherever Soldiers are, whenever needed. Basically, the goals should be to improve and sustain Warfighter health and performance under all conditions.
SAMARITAN EAR PRO (SEP-X) Samaritan Polymer is the next generation of cutting edge battlefield hearing protection. This product will change how the warfighter protects his/ her hearing in the current battlefield environment.
CREATES A CUSTOM PROTECTIVE AND ACOUSTIC NOISE BARRIER FOR THE EAR
Sources
[1] Overview of Agents Used for Emergency Hemostasis
Hadi Khoshmohabat,1 Shahram Paydar,2,3 Hossein Mohammad Kazemi,1 and Behnam Dalfardi1,2,*
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869418/
Holcomb, J. B., McMullin, N. R., Pearse, L., Caruso, J., Wade, C. E., Oetjen-Gerdes, L., … Butler, F. K. (2007). Causes of Death in U.S. Special Operations Forces in the Global War on Terrorism: 2001–2004. Annals of Surgery, 245(6), 986–991. http://doi.org/10.1097/01.sla.0000259433.03754.98
Pryor Medical Devices Wins $14.3MM Contract for REBOA Research. (n.d.) >The Free Library. (2014). Retrieved Apr 11 2018 from https://www.thefreelibrary.com/Pryor+Medical+Devices+Wins+%2414.3MM+Contract+for+REBOA+Research.-a0434324194
Military Times. (2017, August 08). Study: 25% of war deaths medically preventable. Retrieved April 11, 2018, fromhttps://www.militarytimes.com/2013/03/29/study-25-of-war-deaths-medically-preventable/
https://en.wikipedia.org/wiki/Thrombin#cite_note-pmid17660072-23
Chapman WC, Singla N, Genyk Y, McNeil JW, Renkens KL, Reynolds TC, Murphy A, Weaver FA (August 2007). "A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis". Journal of the American College of Surgeons. 205 (2): 256–65. doi:10.1016/j.jamcollsurg.2007.03.020. PMID 17660072.
https://www.researchgate.net/post/Is_allergy_a_real_issue_in_chitosan_from_shellfish_origin
https://www.researchgate.net/profile/Staffan_Palm2